Text Size: A A A      Contrast:        Transparency in Coverage Rule

Diabetic Macular Edema article published in March 2011 issue of Retinal Physician

Retina Associates physicians J.M. Coney MD, J.P. Schartman MD, and L.J. Singerman MD, FACS have recently published an article entitled “Advancing Treatments for Diabetic Macular Edema (DME) - Anti-inflammatory and antiangiogenic options may augment or replace laser”. This article details some exciting new developments of more efficacious treatments for DME, the most common cause of vision loss in patients with diabetes mellitus.

Focal/grid laser photocoagulation is and has been the primary standard of care for treating DME. Some promising research has recently shown positive effects of antiangiogenic agents such as ranibizumab and bevacizumab given intraviteally and of corticosteroids given via intravitreal injection or implanted delivery systems, either alone or when combined with laser treatment. These additional treatments may possibly extend the duration of treatment effect as well as improve the visual prognosis.